Back to search results

Repurposing Atovaquone for Platinum-Resistant Ovarian Cancer

This study is testing if a medication called atovaquone can help women with platinum-resistant ovarian cancer. Platinum-resistant means the cancer has grown within six months of finishing platinum-based chemotherapy. Atovaquone is usually used to treat or prevent certain infections. Researchers want to see if giving atovaquone can improve how long patients live without their cancer getting worse (progression-free survival) compared to standard treatments. You may be able to join if you are an adult woman with platinum-resistant, high-grade serous ovarian cancer and meet other health criteria. The study plans to enroll 28 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 28 participants.
What's involved
You will take atovaquone by mouth. You will also have CT scans and biopsies or paracentesis (a procedure to remove fluid from the abdomen) throughout the study.
Compensation
Not stated in the trial record.
Follow-up
After treatment, you will be followed up for 30 days, and then every 6 months thereafter.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05998135

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Emory University
~28 participants
Updated 2025-09-11 on ClinicalTrials.gov
What's tested:AtovaquoneBiopsyComputed TomographyParacentesis

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression free survival (PFS)
Measured over From initiation of atovaquone to progression or death, assessed up to 1 year

Conditions

Ovarian High Grade Serous Adenocarcinoma
Platinum-Resistant Ovarian Carcinoma

Explore related trials

Malignant Ovarian Neoplasm

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Namita Khanna, MD, MSPH · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute

Who to contact

Namita Khanna, MD, MSPH
[email protected]
404-778-3401
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
There will be no limitations on number of prior lines of therapy
Trial is open to non-English speaking patients
Trial is open to patients referred from community practice

Exclusion

Patients who are \< 18 years old
Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
Patients who are incarcerated
Patients who are unable to provide consent / lack decision-making capacity

What this trial measures

  • Progression free survival (PFS)From initiation of atovaquone to progression or death, assessed up to 1 year

    Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median PFS will be estimated using the Brookmeyer-Crowley approach.